Detail akcie Aurinia Pharma online

Business Summary: Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Aurinia Pharmaceuticals Inc revenues increased 24% to $62.5M. Net income totaled $23.3M vs. loss of $10.7M. Revenues reflect Net product sales increase of 25% to $60M, Revenue Sales of Goods & Services increase of 12% to $2.5M. Net Income reflects Stock-based Compensation in SGA decrease from $7.5M (expense) to $3.5M (income), Labor & Related Expenses in SGA decrease of 44% to $12.1M (expense).